|
|
 Previous Article | Table of Contents | Next Article 
Chronic Expression of Murine flt3 Ligand in Mice Results in Increased Circulating White Blood Cell Levels and Abnormal Cellular Infiltrates Associated With Splenic Fibrosis
Todd S.-C. Juan,
Ian K. McNiece,
Gwenneth Van,
David Lacey,
Cynthia Hartley,
Patricia McElroy,
Yu Sun,
Julie Argento,
David Hill,
Xiao-Qiang Yan, and
Frederick A. Fletcher
From the Departments of Developmental Hematology and Pathology, Amgen, Inc, Thousand Oaks, CA.
The effect of chronic expression of flt3 ligand (FL) on in vivo hematopoiesis was studied. Retroviral vector-mediated gene transfer was used in a mouse model of bone marrow transplantation to enforce expression of mouse FL cDNA in hematopoietic tissues. As early as 2 weeks posttransplantation, peripheral blood white blood cell counts in FL-overexpressing recipients were significantly elevated compared with controls. With the exception of eosinophils, all nucleated cell lineages studied were similarly affected in these animals. Experimental animals also exhibited severe anemia and progressive loss of marrow-derived erythropoiesis. All of the FL-overexpressing animals, but none of the controls, died between 10 and 13 weeks posttransplantation. Upon histological examination, severe splenomegaly was noted, with progressive fibrosis and infiltration by abnormal lymphoreticular cells. Abnormal cell infiltration also occurred in other organ systems, including bone marrow and liver. In situ immunocytochemistry on liver sections showed that the cellular infiltrate was CD3+/NLDC145+/CD11c+, but B220- and F4/80-, suggestive of a mixed infiltrate of dendritic cells and activated T lymphocytes. Infiltration of splenic blood vessel perivascular spaces resulted in vascular compression and eventual occlusion, leading to splenic necrosis consistent with infarction. These results show that FL can affect both myeloid and lymphoid cell lineages in vivo and further demonstrate the potential toxicity of in vivo treatment with FL.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 76-84
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T.S.-C. Juan, B. Bolon, R. A. Lindberg, Y. Sun, G. Van, and F. A. Fletcher
Mice Overexpressing Murine Oncostatin M (OSM) Exhibit Changes in Hematopoietic and Other Organs that Are Distinct from Those of Mice Overexpressing Human OSM or Bovine OSM
Vet. Pathol.,
January 1, 2009;
46(1):
124 - 137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. B. Aiello, J. R. Keller, K. D. Klarmann, G. Dranoff, R. Mazzucchelli, and S. K. Durum
IL-7 Induces Myelopoiesis and Erythropoiesis
J. Immunol.,
February 1, 2007;
178(3):
1553 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Karsunky, M. Merad, A. Cozzio, I. L. Weissman, and M. G. Manz
Flt3 Ligand Regulates Dendritic Cell Development from Flt3+ Lymphoid and Myeloid-committed Progenitors to Flt3+ Dendritic Cells In Vivo
J. Exp. Med.,
July 21, 2003;
198(2):
305 - 313.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Miller, V. G. Pillarisetty, A. B. Shah, S. Lahrs, and R. P. DeMatteo
Murine Flt3 Ligand Expands Distinct Dendritic Cells with Both Tolerogenic and Immunogenic Properties
J. Immunol.,
April 1, 2003;
170(7):
3554 - 3564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Manfra, S.-C. Chen, K. K. Jensen, J. S. Fine, M. T. Wiekowski, and S. A. Lira
Conditional Expression of Murine Flt3 Ligand Leads to Expansion of Multiple Dendritic Cell Subsets in Peripheral Blood and Tissues of Transgenic Mice
J. Immunol.,
March 15, 2003;
170(6):
2843 - 2852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Gilliland and J. D. Griffin
The roles of FLT3 in hematopoiesis and leukemia
Blood,
August 13, 2002;
100(5):
1532 - 1542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Kelly, Q. Liu, J. L. Kutok, I. R. Williams, C. L. Boulton, and D. G. Gilliland
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
Blood,
January 1, 2002;
99(1):
310 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Hawley, A. Z.C. Fong, H. Griesser, S. D. Lyman, and R. G. Hawley
Leukemic Predisposition of Mice Transplanted With Gene-Modified Hematopoietic Precursors Expressing flt3 Ligand
Blood,
September 15, 1998;
92(6):
2003 - 2011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Williams
In Vivo Effects of flt3 Ligand
Blood,
December 15, 1997;
90(12):
5022 - 5022.
[Full Text]
[PDF]
|
|
|
|
|
